{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:59:31Z","timestamp":1787032771335,"version":"build-2736575974"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,24]]},"DOI":"10.7759\/cureus.82958","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T02:53:12Z","timestamp":1745549592000},"source":"Crossref","is-referenced-by-count":1,"title":["Avelumab-Induced Ocular Myasthenia Gravis: A Case Report"],"prefix":"10.7759","author":[{"given":"Rinrada","family":"Khaokong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yit Ting","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thangarajah","family":"Mugunthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx170","article-title":"Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy","volume":"28","author":"Chin K","year":"2017","unstructured":"Chin K, Chand VK, Nuyten DS. Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy. Ann Oncol. 2017, 28:1658-66. 10.1093\/annonc\/mdx170","journal-title":"Ann Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo J","year":"2015","unstructured":"Naidoo J, Page DB, Li BT, et al.. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015, 26:2375-91. 10.1093\/annonc\/mdv383","journal-title":"Ann Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot JM","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, et al.. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016, 54:139-48. 10.1016\/j.ejca.2015.11.016","journal-title":"Eur J Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s1078-1439(01)00185-5","article-title":"Mode of presentation of renal cell carcinoma provides prognostic information","volume":"7","author":"Lee CT","year":"2002","unstructured":"Lee CT, Katz J, Fearn PA, Russo P. Mode of presentation of renal cell carcinoma provides prognostic information. Urol Oncol. 2002, 7:135-40. 10.1016\/s1078-1439(01)00185-5","journal-title":"Urol Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus NE","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015, 14:1023-36. 10.1016\/S1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0b013e31828a0090","article-title":"Correlation between acetylcholine receptor antibody levels and thymic pathology in myasthenia gravis: a review","volume":"14","author":"Huang GZ","year":"2013","unstructured":"Huang GZ, Lo YL. Correlation between acetylcholine receptor antibody levels and thymic pathology in myasthenia gravis: a review. J Clin Neuromuscul Dis. 2013, 14:209-17. 10.1097\/CND.0b013e31828a0090","journal-title":"J Clin Neuromuscul Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious D","year":"2017","unstructured":"Makarious D, Horwood K, Coward JI. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 2017, 82:128-36. 10.1016\/j.ejca.2017.05.041","journal-title":"Eur J Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.33588\/rn.6808.2018497","article-title":"Myasthenia gravis induced by inmuno checkpoints inhibitors: first case report secondary to avelumab therapy and review of published cases (Article in Spanish)","volume":"68","author":"Reyes-Bueno JA","year":"2019","unstructured":"Reyes-Bueno JA, Rodriguez-Santos L, Serrano-Castro PJ. Myasthenia gravis induced by inmuno checkpoints inhibitors: first case report secondary to avelumab therapy and review of published cases (Article in Spanish). Rev Neurol. 2019, 68:333-8. 10.33588\/rn.6808.2018497","journal-title":"Rev Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2019-0106","article-title":"Myasthenia gravis induced by avelumab","volume":"11","author":"Yuen C","year":"2019","unstructured":"Yuen C, Fleming G, Meyers M, Soliven B, Rezania K. Myasthenia gravis induced by avelumab. Immunotherapy. 2019, 11:1181-5. 10.2217\/imt-2019-0106","journal-title":"Immunotherapy"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/355727-avelumab-induced-ocular-myasthenia-gravis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T02:53:13Z","timestamp":1745549593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/355727-avelumab-induced-ocular-myasthenia-gravis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.82958","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,24]]}}}